News, DPC Business Insight, Patient & Physician Edu. | t: (770) 455-1650 |

RETAIL NEWS | Albertsons partners with Personalized Medicine platform provider

STATS | More Female Physicians Entering DPC | More …

Join 2,764 other followers

Listen | All-New Series | FOR DPC

NEW DPC EDU. SERIES | PODCAST | DOWNLOAD Now ... Don't like your Doctor? Is that your fault or your Doctor's? In this 4-part audio series, we expose what can be done. Listen Here ... © 2018 The DPC Journal/DocPreneur Podcast

Industry Insights, 2018

Subscribe to Our Podcast | ALL ACCESS

Gain 10-months (with 2-mos free!) of access to this exclusive Audio Club and Start downloading and listening today!


Books, Resources, Shop


Click here to listen to DPC Podcast, Innovations in the Delivery of Medicine and More Interviews ...

Personalized Medicine Advances With First-Of-Its-Kind Partnership Between Genomind® And Albertsons Sav-On, Jewel-Osco And Acme Sav-On

KING OF PRUSSIA, Pa., May 29, 2018 /PRNewswire/ — Genomind, which has been recognized and awarded for its unique personalized medicine platform, has entered into a partnership with Albertsons Companies, one of the largest food and drug retailers in the United States.

(Read full story below …)

EVIDENZA PRECISION MEDICINE — The Whole Genome Sequencing (WGS) DNA Test & REPORTS for Private Medicine Patients, a Physician Ordered WGS Test Includes … a Saliva Kit + Comprehensive Physician Report + Simple, Easy to Understand Patient Report + Smart Phone App Integration + Storage … LEARN MORE …

The participating locations are:

  • 21 Sav-On pharmacies at Albertsons in Boise, Idaho and nearby communities;
  • 5 Jewel-Osco pharmacies at Jewel-Osco in the Chicago area; and
  • 2 Sav-On pharmacies at Acme in the Philadelphia area.

Both Genomind and Albertsons Companies are hopeful that the number of locations offering the service will increase over time.

“We are excited to bring this opportunity to educate our patients about how genetic testing may be able to help them get better faster as they face mental health challenges. We have reviewed the Genecept Assay from Genomind and feel confident about how its platform can enable an individualized approach to treatment,” says Albertsons Companies Senior Vice President of Pharmacy, Health & Wellness, Mark Panzer.

At the select locations, specially trained pharmacists may decide to counsel a patient if they see a pattern of the patient having unsuccessful experiences with a medicine prescribed for depression, anxiety, obsessive-compulsive disorder or other mental illnesses. For instance, up to half of all patients respond poorly to the first psychiatric medicine they try because everyone’s body is different, partially based upon on their individual genetic makeup.

The pharmacist, if the patient agrees, would then contact the treating clinician and suggest the Genecept Assay. The Assay identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects.

The pharmacist would be able to administer the test in a private area of the pharmacy; it involves collecting a small amount of saliva from the patient’s mouth with a cheek swab.

The pharmacist would review the results of the genetic test with the patient after it’s returned from Genomind’s CLIA-certified lab. The clinician also would receive the test and could use it to help guide treatment decisions.

“We strongly embrace Albertsons Companies’ mission to help people across the country live better lives, and we are honored to now be part of that effort,” says Michael Koffler, President and CEO, Genomind. “Albertsons, Acme, Jewel-Osco and Sav-On are among the most established and respected pharmacies and pharmacists in the communities they serve. We are eager to bring Genomind’s unique platform to their patients.”

The Genecept Assay covers more than 20 drug classes, 122 medications approved by the U.S. Food and Drug Administration, 18 clinically validated genes and 97 percent of medications used to treat depression, anxiety, bipolar disorder, schizophrenia, attention-deficit disorder and autism. It also offers comprehensive coverage of pain medications.

Genecept has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs; further details are available at

About Albertsons Companies
Albertsons Companies is one of the largest food and drug retailers in the United States, with both a strong local presence and national scale. We operate stores across 35 states and the District of Columbia under 20 well-known banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen and Carrs, as well as meal kit company Plated based in New York City. Albertsons Companies is committed to helping people across the country live better lives by making a meaningful difference, neighborhood by neighborhood. In 2017 alone, along with the Albertsons Companies Foundation, the company gave nearly $300 million in food and financial support. These efforts helped millions of people in the areas of hunger relief, education, cancer research and treatment, programs for people with disabilities and veterans outreach.

About Genomind

Precision Medicine Book Bundle — Free Shipping, On Sale —

Genomind® is a unique personalized medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life. Learn more at

About the Genecept Assay

The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at


Kristina Habermann
Vice President, Marketing and Corporate Communications

Adam Shapiro


Chris Irmscher

SOURCE Genomind

Related Links


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

DPC Journal Edu. Author’s Corner | Download …

DPC Journal | Job Board

Insights | Analysis | Latest Trends

(C) 2016, 2017, 2018 | The DPC Journal

Scalability & Startup In DPC

(C) 2017 | The Direct Primary Care Journal - All Rights Reserved. Click to enlarge ...

FOR DPC | Unique Offer For DPC Journal Readers in 2018

The DPC Journal Strategic Partnership with Unique Pediatric & Family Medicine/Ortho. -- “Invented by a mom who spent enough hours in the pediatrician’s office to know that keeping kids calm and occupied would make doctor’s visits easier on everyone …”

Free Shipping, New Bundle!

Different Opinions | Insights | Analysis | Trends

(c) 2017 The Direct Primary Care Journal (The DPC Journal)

Join 2,764 other followers

Popular Audio Downloads | Podcasts

Click here to listen to DPC Podcast, Innovations in the Delivery of Medicine and More Interviews ...

Insights | Analysis | Latest Trends

© 2017 The DPC Journal

%d bloggers like this: